Join the Botanix commercial team and guests for the Company’s Commercial Day Webinar on Tuesday 17 September 10:30am AEST / 8:30am AWST for a comprehensive update on commercial launch plans and market insights for Sofdra™.
Pre-register: Click here
To view Appendix 4E, click here. Mark your calendar for the Company’s Commercial Day Webinar on
Tuesday 17 September 10:30am AEST / 8:30am AWST which will provide a comprehensive update on
commercial launch plans and market insights for Sofdra™. Registration to follow.
Per E&P analyst David Nayagam, Sofdra is poised to provide a new treatment option for primary axillary hyperhidrosis, with “a novel and potentially disruptive model for marketing, reimbursement and distribution.” E&P affirms Speculative Buy and $0.55 Price Targe
Botanix has received firm commitments for $70 million capital raising via an institutional placement. Funds will be applied towards the launch of Sofdra™ (sofpironium) gel, 12.45%, as well as working capital and costs of the placement.
Botanix has submitted the last label materials to the US Food & Drug Administration (FDA) for Sofdra™ a pending prescription treatment for excessive underarm sweating. Label discussions are the final step for Botanix before the anticipated FDA approval of Sofdra and have involved product carton design and wording of information that is provided to patients and physicians about the product.
In new research on Botanix, leading biotech analyst David Nayagam from E&P highlights the “compelling opportunity” that the Company presents and initiates coverage with a speculative buy and $0.55 price target. This increased interest in Botanix comes at a critical time, as we await the commencement of labelling discussions with the FDA – the final regulatory hurdle for Sofdra™ before expected approval in late June 2024.
Euroz Hartleys’ Seth Lizee reviews the Botanix Commercial Day Webinar and maintains a Speculative Buy recommendation with an upgraded $0.33 Price Target.
Lizee expressed increased confidence in the late June FDA approval decision and BOT’s commercial strategy.
Video is now available of the Company’s Commercial Day Webinar presented on 8 May.
The expanded commercial team provides market insights and a comprehensive update on commercial launch plans for Sofdra™, which is expected to be approved in late June 2024.
Botanix co-founder and executive director Matt Callahan has been profiled in The West Australian this week, in an article by journalist Cheyanne Enciso titled “Botanix co-founder Matt Callahan says zig-zag career like ‘drinking from a firehose’ “.
The feature outlines Matt’s extensive experience as founder of several ASX-listed companies, and shares his insights into what makes a successful company.
“I think the strongest lesson for me is to work with people who are world class and be prepared to learn from them, be prepared to build networks with people that ultimately can create a great company.”
